about
CFTR Modulators: Shedding Light on Precision Medicine for Cystic FibrosisHarnessing public domain data to discover and validate therapeutic targets.Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation ProductCysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation.Extracellular chloride is required for efficient platelet aggregation.Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosisSpecific stabilization of CFTR by phosphatidylserine.Precision medicine, genomics and drug discovery.Individualized medicine using intestinal responses to CFTR potentiators and correctors.Cystic Fibrosis and the Nervous System.Viruses in cystic fibrosis patients' airways.Strategies for the etiological therapy of cystic fibrosis.Not All Is CFTR - Neutrophils and Cholesterol in Cystic Fibrosis.Toward inclusive therapy with CFTR modulators: Progress and challenges.Protein folding: Illuminating chaperone activity.The RD-Connect Registry & Biobank Finder: a tool for sharing aggregated data and metadata among rare disease researchers.A Novel Family of Small Molecules that Enhance the Intracellular Delivery and Pharmacological Effectiveness of Antisense and Splice Switching Oligonucleotides.In Vivo Modeling of the Pathogenic Effect of Copper Transporter Mutations That Cause Menkes and Wilson Diseases, Motor Neuropathy, and Susceptibility to Alzheimer's Disease.
P2860
Q28073996-6EA443F7-5999-4DF4-BC89-038C99B0233AQ30491667-4B682C49-86F0-4CFF-A032-C51888E62DE1Q37595212-CBCFA0D9-EB90-44D8-A6ED-983A24C952F1Q37744944-F29D5BC8-35CC-458A-A084-616BF0D18CD1Q38670294-CDA234C9-ED88-4EED-8903-BE6F240A7B87Q38708247-C3A0458D-C447-4A7A-82F8-F3AB14C96F3BQ38787827-FA8A6278-7A24-49F0-917F-08BD37BD42E3Q38931024-5B96E1BC-3469-4734-8FB3-E961FE5F6DDBQ38962735-1D7E9EAD-F270-4E64-B628-09E4B1D496A1Q39017146-E048C0D9-D960-479E-BF33-0F3A88BE6EDAQ39199043-2F88847B-9130-4D3D-9554-85A8F4CCB433Q42650380-D54D18FD-5FE9-4FA6-9D0B-973085DDE38DQ42652155-F3D74204-7BB5-410C-A259-E75E4C374AFBQ47842086-31F9D576-28C7-437F-A9C0-21322340D4D5Q48092471-65BDAC0E-83BB-428C-956E-EFC6BE3520FBQ48112494-B4D8EB23-5203-4158-BEB6-4FBF219836BCQ48132699-EF6BE6C6-D1A0-47B1-94BC-D9CB2734A085Q50934293-32CF328F-4862-4000-A97A-CB2366114D77
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
New and emerging targeted therapies for cystic fibrosis
@ast
New and emerging targeted therapies for cystic fibrosis
@en
New and emerging targeted therapies for cystic fibrosis
@nl
type
label
New and emerging targeted therapies for cystic fibrosis
@ast
New and emerging targeted therapies for cystic fibrosis
@en
New and emerging targeted therapies for cystic fibrosis
@nl
prefLabel
New and emerging targeted therapies for cystic fibrosis
@ast
New and emerging targeted therapies for cystic fibrosis
@en
New and emerging targeted therapies for cystic fibrosis
@nl
P2860
P3181
P356
P1433
P1476
New and emerging targeted therapies for cystic fibrosis
@en
P2093
Bradley S Quon
Steven M Rowe
P2860
P3181
P356
10.1136/BMJ.I859
P407
P577
2016-01-01T00:00:00Z